In addition, a phase III clinical trial showed that osimertinib resulted in significant longer progression-free survival than gefitinib and erlotinib in untreated EGFR-mutated advanced NSCLC [27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.